Separately, Zacks Investment Research raised Cyclacel Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $0.50 price target for the company in a report on Monday, November 18th.
Shares of NASDAQ CYCC opened at $0.52 on Tuesday. The business has a fifty day moving average of $0.42 and a two-hundred day moving average of $0.49. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.65 and a current ratio of 7.65. Cyclacel Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $1.18. The stock has a market cap of $9.46 million, a PE ratio of -0.85 and a beta of 3.19.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.
Further Reading: Key terms to understand channel trading
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.